209 related articles for article (PubMed ID: 33686952)
1. Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2.
Li W; Yuan B; Zhao Y; Lu T; Zhang S; Ding Z; Wang D; Zhong S; Gao G; Yan M
Aging (Albany NY); 2021 Mar; 13(6):8248-8275. PubMed ID: 33686952
[TBL] [Abstract][Full Text] [Related]
2. Computational Study of Novel Natural Inhibitors Targeting O
Yang L; Li W; Zhao Y; Zhong S; Wang X; Jiang S; Cheng Y; Xu H; Zhao G
World Neurosurg; 2019 Oct; 130():e294-e306. PubMed ID: 31203065
[TBL] [Abstract][Full Text] [Related]
3. Computational study of novel natural inhibitors targeting aminopeptidase N(CD13).
Ge J; Wang Z; Cheng Y; Ren J; Wu B; Li W; Wang X; Su X; Liu Z
Aging (Albany NY); 2020 May; 12(9):8523-8535. PubMed ID: 32388498
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome research identifies four hub genes related to primary myelofibrosis: a holistic research by weighted gene co-expression network analysis.
Li W; Zhao Y; Wang D; Ding Z; Li C; Wang B; Xue X; Ma J; Deng Y; Liu Q; Zhang G; Zhang Y; Wang K; Yuan B
Aging (Albany NY); 2021 Oct; 13(19):23284-23307. PubMed ID: 34633991
[TBL] [Abstract][Full Text] [Related]
5. Immunoproteasome Genes Are Modulated in CD34
Di Rosa M; Giallongo C; Romano A; Tibullo D; Li Volti G; Musumeci G; Barbagallo I; Imbesi R; Castrogiovanni P; Palumbo GA
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32331228
[TBL] [Abstract][Full Text] [Related]
6. In silico identification of natural product inhibitors of JAK2.
Zhong HJ; Lin S; Tam IL; Lu L; Chan DS; Ma DL; Leung CH
Methods; 2015 Jan; 71():21-5. PubMed ID: 25038528
[TBL] [Abstract][Full Text] [Related]
7. Expression profile analysis reveals hub genes that are associated with immune system dysregulation in primary myelofibrosis.
Ma H; Liu J; Li Z; Xiong H; Zhang Y; Song Y; Lai J
Hematology; 2021 Dec; 26(1):478-490. PubMed ID: 34238135
[TBL] [Abstract][Full Text] [Related]
8. Advances in the understanding and management of primary myelofibrosis.
Cervantes F; Pereira A
Curr Opin Oncol; 2011 Nov; 23(6):665-71. PubMed ID: 21892083
[TBL] [Abstract][Full Text] [Related]
9. Computer-aided discovery of aminopyridines as novel JAK2 inhibitors.
Zhao C; Yang SH; Khadka DB; Jin Y; Lee KT; Cho WJ
Bioorg Med Chem; 2015 Mar; 23(5):985-95. PubMed ID: 25650310
[TBL] [Abstract][Full Text] [Related]
10. Computational study on new natural compound agonists of stimulator of interferon genes (STING).
Zhong S; Li W; Bai Y; Wu B; Wang X; Jiang S; Zhao Y; Ren J; Li H; Jin R
PLoS One; 2019; 14(5):e0216678. PubMed ID: 31120925
[TBL] [Abstract][Full Text] [Related]
11. Effective natural inhibitors targeting poly ADP-ribose polymerase by computational study.
Zhong S; Wu B; Yang W; Ge J; Zhang X; Chen Z; Duan H; He Z; Liu Y; Wang H; Jiang Y; Zhang Z; Wang X; Li W; Liu N; Guo X; Mou Y
Aging (Albany NY); 2021 Jan; 13(2):1898-1912. PubMed ID: 33486472
[TBL] [Abstract][Full Text] [Related]
12. Investigational Janus kinase inhibitors in development for myelofibrosis.
Bose P; Abou Zahr A; Verstovsek S
Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening.
Bajusz D; Ferenczy GG; Keserű GM
J Chem Inf Model; 2016 Jan; 56(1):234-47. PubMed ID: 26682735
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
[TBL] [Abstract][Full Text] [Related]
15. Novel natural inhibitors targeting B-RAF(V600E) by computational study.
Wu B; Zhang Z; Dou G; Lv X; Ge J; Wang H; Xie H; Zhu D
Bioengineered; 2021 Dec; 12(1):2970-2983. PubMed ID: 34252351
[TBL] [Abstract][Full Text] [Related]
16. Computational study on natural compounds inhibitor of c-Myc.
Ren J; Huangfu Y; Ge J; Wu B; Li W; Wang X; Zhao L
Medicine (Baltimore); 2020 Dec; 99(50):e23342. PubMed ID: 33327259
[TBL] [Abstract][Full Text] [Related]
17. Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors.
Yang M; Tao B; Chen C; Jia W; Sun S; Zhang T; Wang X
J Chem Inf Model; 2019 Dec; 59(12):5002-5012. PubMed ID: 31746601
[TBL] [Abstract][Full Text] [Related]
18. Comparison of JAK2
Latagliata R; Polverelli N; Tieghi A; Palumbo GA; Breccia M; Sabattini E; Villari L; Riminucci M; Valli R; Catani L; Alimena G; Ottaviani E; Fama A; Martinelli G; Perricone M; Spinsanti M; Cavo M; Vianelli N; Palandri F
Hematol Oncol; 2018 Feb; 36(1):269-275. PubMed ID: 28509339
[TBL] [Abstract][Full Text] [Related]
19. Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres.
Mukthavaram R; Ouyang X; Saklecha R; Jiang P; Nomura N; Pingle SC; Guo F; Makale M; Kesari S
J Transl Med; 2015 Aug; 13():269. PubMed ID: 26283544
[TBL] [Abstract][Full Text] [Related]
20. Predicting protein targets for drug-like compounds using transcriptomics.
Pabon NA; Xia Y; Estabrooks SK; Ye Z; Herbrand AK; Süß E; Biondi RM; Assimon VA; Gestwicki JE; Brodsky JL; Camacho CJ; Bar-Joseph Z
PLoS Comput Biol; 2018 Dec; 14(12):e1006651. PubMed ID: 30532261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
